Market Cap
₹30,906 Cr.
P/E
54.77
Quick View
  • 1d
  • 1m
  • 6m
  • YTD
  • 1y
  • 3y
  • 5y
  • 10y
  • max

Company Timeline

Forensics
Other Income
Other Income is not affecting ratios of the company
Capex vs ROCE
ROCE of the company has decreased even without significant capex
Pledge
Promoters have not pledged a significant portion of their holding
Revenue Recognition
Company is converting accounting profit to cash
Depreciation Effect
Depreciation accounting is not leading to increase in profits
Contingent Liabilities
Company does not have significant contingent liabilities
Retail Holding
Retail has been selling the stock which is usually a good time to buy
Share price
Share price has increased over last 10 years due to earnings
ROE
Asset Turnover is responsible for ROE increase over last 10 years
Working Capital
Company has significant working capital which is dragging its ROCE and ROE
Debt
Company should not have issues servicing its debt
Promoter Holding
Promoter has not sold any shares in the last 90 days
Current vs Historic Valuation
Company is trading at a premium to 3 year historic valuations
ROE
Latest
8.07%
3yr Average
16.16%
5yr Average
15.9%
Net Profit Margin
Latest
7.6%
3yr Average
14.66%
5yr Average
13.8%
ROCE
Latest
11.64%
3yr Average
19.61%
5yr Average
18.97%
Debt to Equity
Latest
0.25
3yr Average
0.15
5yr Average
0.15
Market Share
0.81% (as of Jul 22)
Anti - Diabetes - Market Share
1.03% (as of Jul 22)
Anti-Infectives - Market Share
55.08% (as of Nov 21)
Anti-Malarial - Market Share
3.84% (as of Nov 21)
Antineo Plastic - Market Share
0.11% (as of Nov 21)
Blood Related - Market Share
2.09% (as of Jul 22)
Cardiovascular - Market Share
1.20% (as of Nov 21)
Dermatology - Market Share
0.12% (as of Nov 21)
Endocrinology - Market Share
1.02% (as of Jul 22)
Gastro-Intestinal - Market Share
1.11% (as of Nov 21)
Neurological - Market Share
0.55% (as of Nov 21)
Ophthalmology - Market Share
8.06% (as of Nov 21)
Pain - Market Share
1.80% (as of Dec 22)
Pharmaceutical Sector - Market Share
0.83% (as of Nov 21)
Respiratory - Market Share
0.39% (as of Jul 22)
Sex Stimulants - Market Share
2.23% (as of Nov 21)
Urology - Market Share
0.43% (as of Jul 22)
Vitamin & Dietary Supplements - Market Share
Show more
Revenue mix

Product Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Wise Break-Up - Domestic

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Branded Generics

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -Generics

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up -API

locked
Source
|
Latest
|
locked
Historic

Location Wise Break-Up

locked
Source
|
Latest
|
locked
Historic

Therapeutic Area Break-Up

locked
Source
|
Latest
|
locked
Historic
Show more
Operational Metrics

    Select a Metric
    • US DMF Filings (.)
    • Number of ANDA's Filed in USA (.)
    • Number of ANDA's Approved By USFDA (.)
    • Domestic Sales Growth - YoY (%)
    • R&D as a % of Total Sales (%)
    Peer Comparison
    Suppliers
    Company Filing
    Show Previous Years
    Discussions & Analysis